Infectious Disease Clinical Development Expertise

Getting a novel infectious disease vaccine or treatment on the market today is extremely critical and complex. 

Infectious diseases are a threat to global health and way of life everywhere – particularly in the midst of the current COVID-19 pandemic. Time is of the essence when it comes to developing safe and effective infectious disease vaccines and treatments.  In addition to recent pandemic outbreaks caused by viral infections, more treatment-resistant bacterial and fungal infections are rising, with antibiotics and antifungals becoming less effective.

Our scientific-minded infectious disease experts can help navigate this challenging landscape, having conducted more than 300 projects for Infectious Disease treatments and vaccines.

Experience Battling Infectious Diseases

Whether you are aiming to prevent or combat a viral, bacterial, fungal or parasitic infection, Veristat can help make the difference for your study’s success. Our teams understand the nuances and difficulties involved with treating infectious diseases, have the experience to perform vaccine trials, and are adept with rapid response to global pandemics that arise, such as the current COVID-19 outbreak response.   

At Veristat, our experienced teams are poised to plan and implement these efforts quickly providing:    

Recent Pandemic Experience
Veristat_icon_infectious disease-216

> 250

Projects for infectious disease treatments and vaccines


50+ COVID-19


50+ Influenza

vaccine programs

8 Ebola

vaccine projects for 2014 outbreak

Explore Our Recent Infectious Disease Experience

Prevention and Treatment of Bacterial & Fungal Infections
   Acinetobacter Baumannii Infections     Gram-Negative Infections 
   Acute Bacterial Skin and Skin Structure Infections (ABSSI)     H. Pylori Infection 
   Bacterial Pneumonia     Joint infection 
   Botulinum vaccine     Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia 
   Candidemia     Nasal Infection 
   Clostridium Difficile (C.Diff)     Nontuberculous Mycobacterial (NTM) Lung Disease 
   Complicated Intra-Abdominal Infections (cIAI)     Nosocomial Infection 
   Complicated Skin and Skin Structure Infection (CSSSI)     Onychomycosis  
   Complicated Urinary Tract Infection including Pyelonephritis     Staphylococcus Aureus 
   Cystic Fibrosis-Pseudomonas      Surgical Site Infections 
   Endocarditis     Vacomycin-Resistant Enterococcal Infections  


Prevention and Treatment of Viruses/Viral Infection​
   COVID 19     Influenza - Pandemic 
   Cytomegalovirus (CMV) Infection     Lassa Fever 
   Ebola    Malaria
   Epstein Barr Virus (EBV)     Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 
   Hepatitis A, B & C    Recurrent Respiratory Papillomatosis (RRP) 
   Herpes (HSV2)    Respiratory Syncytial Virus 
   HIV / AIDS    RNA Vaccine Platforms for multiple types of Infectious Diseases/Cancers 
   Human Papilloma Virus (HPV)     Shingles - Varicella-Zoster Virus (VZV) 
   Influenza - H1N1     Smallpox
   Influenza - H5N1     Sexually Transmitted Infections 
   Influenza - Seasonal     Typhoid Fever 
   Influenza (Universal Vaccine)     West Nile Virus 



Learn More with These Resources


Marketing Applications Approval Record

Veristat is proud to have supported the preparation of 75 marketing applications (NDA, BLA, MAA, etc) that are now approved for patients. For these approved products, ...


Webinar Presentation

Webinar Presentation: Expanding your Clinical Trial into ...

Get the webinar presentation  on how, why and when to expand your clinical trial program into the US, including differences between IND and CTA.


Webinar Video Replay

A Webinar Replay | Expanding your Clinical Trial into the ...

Watch the on-demand webinar  on how, why and when to expand your clinical trial program into the US, including differences between IND and CTA

Request A Proposal